October 29, 2020 -- Takeda Pharmaceutical will import and distribute 50 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, starting in the first half of 2021, pending licensure in Japan, as part of a three-way agreement with Takeda, Moderna, and the government of Japan.
This announcement follows the establishment of Takeda's manufacturing capabilities to produce Novavax' COVID-19 vaccine candidate in its Japan-based facilities. Takeda's efforts to bring Moderna's and Novavax' COVID-19 vaccine candidates to Japan are supported by the Ministry of Health, Labour, and Welfare and the Japan Agency for Medical Research and Development.
Under the terms of the agreement, Takeda will be responsible for securing the necessary regulatory approvals prior to distributing the 50 million doses in Japan. Moderna will provide the finished product and will support Takeda with its development and regulatory efforts.